

EMA/99888/2022

European Medicines Agency decision

P/0086/2022

of 11 March 2022

on the acceptance of a modification of an agreed paediatric investigation plan for isoflurane (Sedaconda and associated names), (EMEA-002320-PIP01-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0086/2022

of 11 March 2022

on the acceptance of a modification of an agreed paediatric investigation plan for isoflurane (Sedaconda and associated names), (EMA-002320-PIP01-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0092/2019 issued on 22 March 2019 and the decision P/0190/2020 issued on 15 May 2020,

Having regard to the application submitted by Sedana Medical AB on 14 October 2021 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 January 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for isoflurane (Sedaconda and associated names), inhalation vapour, liquid, inhalation use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Sedana Medical AB, Vende vägen 89, SE-182 32 – Danderyd, Sweden.

EMA/PDCO/603222/2021
Amsterdam, 21 January 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-002320-PIP01-17-M02

Scope of the application

Active substance(s):

Isoflurane

Invented name:

Sedaconda and associated names

Condition(s):

Sedation of mechanically ventilated patients

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Inhalation vapour, liquid

Route(s) of administration:

Inhalation use

Name/corporate name of the PIP applicant:

Sedana Medical AB

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Sedana Medical AB submitted to the European Medicines Agency on 14 October 2021 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0092/2019 issued on 22 March 2019 and the decision P/0190/2020 issued on 15 May 2020.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 22 November 2021.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Sedation of mechanically ventilated patients

The waiver applies to:

- the paediatric population from birth to less than 3 years of age;
- inhalation vapour, liquid, inhalation use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric investigation plan

2.1. Condition:

Sedation of mechanically ventilated patients

2.1.1. Indication(s) targeted by the PIP

Sedation of mechanically ventilated patients

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Inhalation vapour, liquid

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an age-appropriate device/system to allow treatment of children from 3 years of age with isoflurane during mechanical ventilation
Non-clinical studies	0	Not applicable
Clinical studies	1	Study 2 (SED002) Randomized active controlled study to compare efficacy and safety of inhaled isoflurane delivered by the AnaConDa device to intravenous midazolam for sedation in mechanically ventilated children admitted to a paediatric intensive care unit or with a planned ICU admission and requiring mechanical ventilation and sedation for at least 12 hours

Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By February 2023
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Sedation of mechanically ventilated patients

Authorised indication(s):

- Sedation of mechanically ventilated adult patients during intensive care

Authorised pharmaceutical form(s):

Inhalation vapour, liquid

Authorised route(s) of administration:

Inhalation use